"Neoplasm Metastasis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
| Descriptor ID |
D009362
|
| MeSH Number(s) |
C04.697.650 C23.550.727.650
|
| Concept/Terms |
Neoplasm Metastasis- Neoplasm Metastasis
- Metastases, Neoplasm
- Neoplasm Metastases
- Metastasis
- Metastases
- Metastasis, Neoplasm
|
Below are MeSH descriptors whose meaning is more general than "Neoplasm Metastasis".
Below are MeSH descriptors whose meaning is more specific than "Neoplasm Metastasis".
This graph shows the total number of publications written about "Neoplasm Metastasis" by people in this website by year, and whether "Neoplasm Metastasis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 6 | 7 |
| 1997 | 3 | 4 | 7 |
| 1998 | 2 | 9 | 11 |
| 1999 | 2 | 3 | 5 |
| 2000 | 4 | 6 | 10 |
| 2001 | 2 | 5 | 7 |
| 2002 | 2 | 5 | 7 |
| 2003 | 3 | 11 | 14 |
| 2004 | 6 | 22 | 28 |
| 2005 | 5 | 15 | 20 |
| 2006 | 3 | 12 | 15 |
| 2007 | 1 | 11 | 12 |
| 2008 | 8 | 15 | 23 |
| 2009 | 7 | 17 | 24 |
| 2010 | 6 | 18 | 24 |
| 2011 | 5 | 19 | 24 |
| 2012 | 5 | 16 | 21 |
| 2013 | 5 | 27 | 32 |
| 2014 | 9 | 35 | 44 |
| 2015 | 6 | 22 | 28 |
| 2016 | 2 | 35 | 37 |
| 2017 | 2 | 33 | 35 |
| 2018 | 4 | 26 | 30 |
| 2019 | 5 | 40 | 45 |
| 2020 | 4 | 36 | 40 |
| 2021 | 6 | 22 | 28 |
| 2022 | 0 | 6 | 6 |
| 2023 | 1 | 4 | 5 |
| 2024 | 2 | 16 | 18 |
| 2025 | 2 | 13 | 15 |
| 2026 | 0 | 14 | 14 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neoplasm Metastasis" by people in Profiles.
-
Early detection of invasive lung cancer and multiorgan metastasis by a collagen-targeted protein MRI contrast agent. Sci Adv. 2026 Sep 11; 12(37):eadz6815.
-
Addition of High-Dose Vitamin D3 to Standard Treatment in Patients With Metastatic Colorectal Cancer: The SOLARIS Randomized Clinical Trial (Alliance A021703). JAMA. 2026 Sep 01; 336(9):746-754.
-
Enfortumab Vedotin plus Pembrolizumab as First-line Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Results from EV-202 Cohort 9. Clin Cancer Res. 2026 Aug 14; 32(16):3531-3539.
-
[177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial. Lancet. 2026 Aug 29; 408(10557):793-807.
-
Evolving Treatment Paradigms in Hormone Receptor-Positive, Human Epidermal Growth Factor 2-Negative Metastatic Breast Cancer. Am Soc Clin Oncol Educ Book. 2026 Jun; 46(3):e520518.
-
131I-LNTH-1095 Radioligand Therapy plus Enzalutamide versus Enzalutamide Alone in Men with PSMA-Avid Metastatic Castration-Resistant Prostate Cancer: A Phase II Study. Clin Cancer Res. 2026 May 15; 32(10):1973-1982.
-
Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trial. Nat Commun. 2026 May 08; 17(1).
-
Disparities in Disease Presentation and Treatment Initiation for De Novo Metastatic Breast Cancer. JAMA Netw Open. 2026 04 01; 9(4):e268908.
-
Phase II Trial of Interleukin-12 Followed by Interferon Alfa-2b in Patients with Metastatic Malignant Melanoma: Results from CALGB 500001 (Alliance). Cancer Immunol Res. 2026 Mar 04; 14(3):423-433.
-
Cytomorphologic and molecular characterization of metastatic renal cell carcinoma diagnosed by fine-needle biopsy: a single-institution study. J Am Soc Cytopathol. 2026 May-Jun; 15(3):197-206.